Site Editor
Gregory J. Riely, MD, PhD
Gregory J. Riely, MD, PhD
Posted: Friday, September 2, 2022
Findings from the phase III JAVELIN Lung 100 trial were presented at the International Association for the Study of Lung Cancer (IASLC) World Conference on Lung Cancer (WCLC) 2022 (Abstract OA15.03). The goal was to compare first-line avelumab monotherapy (two-dose schedules) with platinum-based doublet chemotherapy in patients with previously untreated PD-L1–positive advanced non–small cell lung cancer (NSCLC). Keunchil Park, MD, PhD, of the Sungkyunkwan University School of Medicine, Seoul, Korea, and colleagues reported the trial did not meet its primary objective, with no significant differences observed in overall and progression-free survival between the treatments.
A total of 1,214 patients with PD-L1–positive tumors (≥ 1 % of tumor cells) initially were randomly assigned on a 1:1 basis to receive avelumab at 10 mg/kg every 2 weeks or platinum-based doublet chemotherapy intravenously every 3 weeks. However, the protocol was amended to adjust patient assignments based on pharmacokinetics and exposure analyses. Patients were then randomly assigned on a 1:2:2 basis to receive avelumab at 10 mg/kg every 2 weeks (n = 366), platinum-based doublet chemotherapy every 3 weeks (n = 526), or avelumab at 10 mg/kg weekly (n = 322) for 12 weeks and every 2 weeks thereafter.
Overall findings revealed no statistically significant differences in overall or progression-free survival between each of the avelumab arms compared with the chemotherapy arm. Treatment-emergent adverse events were also recorded, and events were reported in 95.8%, 96.9%, and 96.8% of patients given avelumab every 2 weeks, avelumab weekly, and chemotherapy, respectively. Additionally, grade 3 or higher adverse events were reported in each arm.
Disclosure: For full disclosures of the study authors, visit. iaslc.org.
World Conference on Lung Cancer 2022
JNCCN Spotlights
